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Temperature-scan X-ray scattering was used to study the effect of the fusion peptide of simian immunodeficiency virus (SIV) on the lipid
polymorphism of N-methylated dioleoylphosphatidylethanolamine (DOPE-Me), in the presence and absence of one or both of the fusion
inhibitors carbobenzoxy-D-phenylalanine-L-phenylalanine-glycine and 1-lauroyl-2-hydroxy-sn-glycero-3-phosphocholine (LPC). Using X-
ray diffraction at stations 2.1 and 8.2 of the Synchrotron Radiation Source at Daresbury Laboratory, UK, the structure of multilamellar
vesicles (MLVs) was probed as the temperature was raised from 20 to 90 jC. The results are compared to those of similar studies, reported
earlier, that used the fusion peptide of feline leukaemia virus (FeLV) which, at 28 amino acid residues in length, is considerably longer than
the SIV peptide (12 amino acid residues). We interpret the results within the framework of current understanding of membrane fusion, and
demonstrate how observed lipid polymorphism might describe the fusion process.
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The fusion of phospholipid bilayers is an integral part of
a number of biological processes, including mitosis, exocy-
tosis, spermatozoid–egg fusion and viral infection [1].0005-2736/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2003.09.003
Abbreviations: CBZ-D-FFG, carbobenzoxy-D-phenylalanine-L-phenyl-
alanine-glycine; dH, lattice repeat distance (hexagonal phase phospholipid);
dL, lattice repeat distance (lamellar phase phospholipid); dQ, lattice repeat
distance (cubic phase phospholipid); DOPC, dioleoylphosphatidylcholine;
DOPE, dioleoylphosphatidylethanolamine; DOPE-Me, N-methylated dio-
leoylphosphatidylethanolamine; EDTA, ethylenediaminetetra-acetic acid;
FeLV, feline leukaemia virus; H, hexagonal phase; L, lamellar phase; LPC,
1-lauroyl-2-hydroxy-sn-glycero-3-phosphocholine; MLV, multilamellar
vesicle; p15EK, fusion peptide from spike protein p15E of FeLV;
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small angle X-ray scattering; SIV, simian immunodeficiency virus; TH,
temperature at which hexagonal phase is first observed; TQ, temperature at
which cubic phase is first observed
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Canada K0J 1J0.However, the molecular rearrangements of the lipids and
the precise kinetic events involved are still uncertain. This is
largely because the fusion event is transient and involves
only local, isolated patches of lipid. It is clear that biomem-
brane fusion is a protein-regulated event [2,3]. In order to
introduce their infective nuclear material into a host cell,
enveloped virus particles use membrane fusion, catalysed by
specialised, extra-membranous glycoprotein ‘spike’, of
which the best known is hemagglutinin of the influenza A
virus. Viral fusion proteins usually contain a highly con-
served N-terminal region that has been shown to be crucial
to the process of fusion between the viral envelope and a
membrane of the host cell during the infection process.
Short peptides (10 to 30 residues long) of corresponding
sequence, termed fusion peptides, retain much of the mem-
brane fusion activity of the larger protein, albeit with slower
rates and lack of a specific binding function. They have
enabled research on membrane fusion mechanisms to focus
on the fundamental interactions between peptide and phos-
pholipid, in isolation from membrane proteins, and their
added levels of complexity.
The precise molecular events that occur during peptide-
induced membrane fusion are still unclear. The membrane
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range into highly curved intermediates prior to fusion pore
development [4,5]. These intermediates can also be induced
by fusion peptides. It has been demonstrated that peptides
that lower the bilayer (La)-to-inverted hexagonal (HII)
phase-transition temperature in model membranes can also
promote membrane fusion through this kind of bilayer
destabilization [6]. It is recognised that a large fraction of
the lipids of many biological membranes form the HII phase
when purified and hydrated under physiological conditions
[7]. These lipids have been termed nonbilayer lipids in
contrast to the bilayer lipids that form lamellar structures
under the same conditions. It has been suggested that,
although membranes are bilayers most of the time, the high
concentration of nonbilayer lipids has functional signifi-
cance in allowing the membranes to form transient non-
bilayer structures because vital processes, including fusion,
would be topologically impossible with intact bilayers.
A concept that has proved very useful in the attempts to
understand fusion peptide activity has been monolayer
curvature strain. Indeed, it has been proposed that this
property is homeostatically controlled in living biomem-
branes [8]. Current models of fusion peptide function are
usually based upon their effect on the monolayer curvature
strain of the membranes involved in the fusion process. The
peptides are thought to destabilise lamellar bilayers by
increasing the hydrophobic volume of a monolayer, relative
to the volume of the solvated polar groups [9].
Highly curved lipid mesomorphs, similar to those in-
volved in the fusion process, recently were directly observed
for the first time with diphytanoyl-phosphocholine lipids,
however, under non-physiological, dehydrated conditions
[10]. Similar structures are suspected to occur during the La-
to-QII (inverted cubic) phase transition and the La-to-HII
phase transition [11]. The ability of a number of agents to
promote fusion appears to be correlated to their ability to
lower the La-to-HII-transition temperature (TH) [12–14].
Similarly, some fusion inhibitors raise TH [15]. Although the
QII and the HII phases, which are kinetically stable, are
unlikely to exist at the site of a developing fusion pore,
knowledge about the topology of the interface as these
phases begin to form has clear implications for our under-
standing of biological fusion mechanisms.
This paper describes a continuation of the work previ-
ously reported [16,17] in which we have used temperature-
scan X-ray scattering to study the effect of the fusion
peptide of feline leukaemia virus (FeLV) on the lipid
polymorphism of N-methylated dioleoylphosphatidyletha-
nolamine (DOPE-Me). In the more recent paper, we have
reported how the tri-peptide carbobenzoxy-D-phenylalanine-
L-phenylalanine-glycine (CBZ-D-FFG) and the lipid 1-
lauroyl-2-hydroxy-sn-glycero-3-phosphocholine (LPC)
modify the phase transition of this lipid. Here we extend
the studies to a different fusion peptide, that from simian
immunodeficiency virus (SIV), and discuss the findings for
this peptide in the context of the model of membrane fusionpresented in the earlier paper [17]. The work also related to
a study of SIV peptide on phospholipid phase transitions by
Colotto et al. [18], who collected X-ray diffraction data at a
range of constant temperatures, ranging from 15 to 80 jC.2. Materials and methods
2.1. Sample preparation
The fusion peptide from the GP160 protein of SIV
(Macaque isolate, SWISSPROT accession number P05885,
sequence GVFVLGFLGFLA), and the fusion peptide p15EK
of FeLV (strain C/Sarma, SWISSPROT accession number
P06752, sequence EPISLTVALMLGGLTVGGIAAGVGT-
GTK), were synthesised and purified by Albachem (Edin-
burgh, Scotland). CBZ-D-FFG was obtained from Sigma (St.
Louis, MO). LPC and DOPE-Me were purchased from
Avanti Polar Lipids (Alabaster, AL) and used without further
purification.
Multilamellar vesicles (MLVs) were prepared by rehyd-
rating phospholipid films as previously described [16,17].
The buffer used for rehydration was 20 mM PIPES, 1 mM
EDTA, 150 mM sodium chloride and 0.3 mM sodium azide
at pH 7.4. All samples had a low lipid concentration of 100
mM, equivalent to 7.57% (w/v), to ensure an excess water
condition. The lipid dispersions were then subjected to five
freeze–thaw cycles. Repeated freezing and thawing across
the chain-melt temperature ensures that the lipid is fully
hydrated regardless of the thermal history of the lipid.
2.2. Temperature-resolved X-ray diffraction
The X-ray diffraction experiments were performed at
stations 2.1 and 8.2 of the Synchrotron Radiation Source at
Daresbury Laboratory, UK. The experimental set-up at the
two instruments was essentially identical. The X-ray wave-
length was 0.154 nm. The specimen-to-detector length was
approximately 1.5 m. Each sample was contained in a glass
capillary tube, held in a steel block with electronic (Linkam)
programmable temperature control. A thermocouple fixed to
the sample chamber monitored the temperature continuously
and wrote the temperature into the data files. The temper-
ature increased in a linear fashion at a rate of 30 K/h, a rate
originally chosen because the metastable cubic phase of
DOPE-Me is not normally observed. Each frame of data
collection lasted for 30 s. The effect of thermal radiation
from X-ray beams of this kind was minimal. Aluminium
foils were added to attenuate the incident beam until no loss
of diffracted intensity was observed throughout the duration
of a complete temperature scan.
2.3. Data analysis
The program XOTOKO [19] was used to correct for
sample thickness and variations in detector response, and to
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determined by measuring a fixed source, 59Fe, overnight
both before and after data collection. Calibration of the x-
axis for small angle scattering was achieved by using rat-tail
collagen as a standard [20]. This calibration was repeated
prior to the exposure of each new sample. The location,
width and amplitude of each Bragg peak were determined
by fitting Lorentzian distributions (PeakFit, SPSS Ltd.).3. Results and discussion
Fig. 1 shows the relationship between lattice basis vector
length and temperature for all observed phases of DOPE-Me
with respect to temperature. Fig. 2 is a schematic summary
of the phase behaviour of DOPE-Me in the presence of SIV
fusion peptide and/or fusion inhibitors, as a function of
temperature. Relevant data from our earlier papers [16,17]
are reproduced for comparison.
3.1. SIV and FeLV
In earlier papers [16,17], we have discussed the effects of
the fusion peptide from feline leukaemia virus (FeLV); with
the current data, we are now able to compare the two
peptides in terms of their effects upon the phase behaviour
of DOPE-Me. Each of the peptides is thought to be helical
in its active form [21] and Brasseur has proposed that both
insert at an oblique angle into phospholipid bilayers. To
date, this has only been determined experimentally for SIV
[22], though a molecular dynamics study of a related fusion
peptide from human immunodeficiency virus also showed
oblique insertion [23]. The most striking difference between
the two peptides used in this study is their length. FeLV
peptide, with 28 amino acids, is considerably longer than
SIV peptide, with only 12. In a-helical conformation, this
corresponds to a length of 42 A˚ for FeLV peptide and 18 A˚
for SIV. Clearly, FeLV peptide may span an entire bilayer,
even at a tilt, while SIV reaches across just one leaflet. This
may explain why FeLV fusion peptide is always more
potent than SIV, in terms of its effects on the phase
behaviour of DOPE-Me.
3.1.1. Lamellar phase
Both peptides reduce the temperature of breakdown for
the lamellar phase, SIV by 5 jC and FeLV by more than 10
jC. This may be a direct consequence of the peptides’
length. Whereas SIV is easily incorporated in two popula-
tions in DOPC bilayers [22] and its influence is directed
more towards individual monolayers, the hydrophobic
length of FeLV requires a full bilayer to span, thus its
influence on bilayer breakdown is more direct.
3.1.2. Hexagonal phase
The hexagonal phase is the dominant high-temperature
phase for DOPE-Me both with and without FeLV. Thelamellar to hexagonal transition is narrow, and in pure
DOPE-Me there is a brief coexistence region. SIV, on the
other hand, induces a gap between the phases where no
structure is present. This brief dissolving of the lipids is
perhaps expected, if we consider that SIV acts on individual
leaflets, rather than the entire bilayer, making it easier to
form micellization products. An important difference be-
tween the actions of the two peptides is that while FeLV
peptide lowers TH (by 6 jC), the SIV peptide raises TH (by
10 jC). The hexagonal phase repeating structural motif is
essentially a bilayer. Although FeLV partitions more easily
in such a phase than actual lamellar bilayers, the direct
influence of SIV on monolayers means that it is readily
incorporated into non-bilayer phases, as we shall see. At 2%
SIV, the hexagonal phase is eliminated altogether. However,
since inverse hexagonal phase is not observed in samples
cooled back to 20 jC without a fusion peptide present, it
appears that SIV peptide does indeed stabilise this phase, in
keeping with our previous observation that inverse hexag-
onal phase is closely related to the fusion process. The
importance of the lamellar to hexagonal pathway in fusion
will be discussed in a later section.
3.1.3. Cubic phase
Both FeLV and SIV have similar effects of lowering TQ,
SIV by 10 jC, and FeLV by as much as 20 jC. With 1%
SIV, the cubic phase comes to dominate the high T regions,
eventually coexisting with a lesser hexagonal phase. The
cubic phase with FeLV and 2% SIV is only transient;
however, the SIV-induced cubic phase is shifted 15 jC to
higher T. In addition, with FeLV the cubic gives way to the
hexagonal phase but with SIV the lipid loses all structure. In
all cases, the cubic phase is metastable; this phase was
observed in samples that had been allowed to cool back to
room temperature. The only means to return the sample to
pure bilayer form is to incubate the sample for at least 1
h well below the main transition of the lipid.
In terms of its effect upon TH and TQ, 2% SIV peptide is
clearly not as potent as 1% SIV. This could be caused by
aggregation of the hydrophobic peptide, as we have previ-
ously speculated for FeLV peptide [24], or it could be that the
phospholipid monolayer curvature strain becomes ‘‘saturat-
ed’’ between 1% and 2% SIV peptide. Support for the latter
comes from similar measurements in the presence of fusion
inhibitors, where the 2% peptide produces a lower onset
temperature than 1% peptide for the HII phase in the presence
of either LPC or CBZ-D-FFG. In addition, the QII phase that
eventually forms in the presence of 2% SIV peptide has a
smaller dQ, and therefore a tighter Gaussian curvature, than
that which forms with lower concentrations of the peptide.
3.2. CBZ-D-FFG and LPC
In our previous work on FeLV, the fusion inhibitors had a
clear and pronounced opposite effect to that of the peptide
itself. Both CBZ-D-FFG and LPC reversed the HII promot-
Fig. 1. The relationship of the d-repeat (A˚) to temperature (jC) for all observed phases of DOPE-Me as determined by temperature-scan X-ray scattering at
stations 2.1 and 8.2 of the Synchrotron Radiation Source at Daresbury Laboratory. (A) Lamellar; (B) inverse hexagonal (HII); (C) inverse cubic (QII). For ease
of comparison, the vertical scale is the same for all three panels, though displaced by 120 A˚ in panel C. Only alternate data points are shown, for clarity. The
inset figure in panel B is an enlarged version of the HII plot.
T.A. Harroun et al. / Biochimica et Biophysica Acta 1617 (2003) 62–68 65ing effects of FeLV, and promoted large d-spacing cubic
phases, and some lamellar stability instead. With SIV, the
fusion inhibitors once again counteract the peptide’s effectson non-lamellar phases; however, this time, they allow for
the presence of a metastable HII phase along with the typical
cubic phase.
     
          
  
          
   
 
  
          
   
          
    
          
  
         
  
 
     
          
  
          
    
          
   
         
  
      
    
          
  
          
     
         
   
          
   
      
Fig. 2. Schematic summary of the phase behaviour of MLVs of DOPE-Me and DOPE-Me with fusion peptides from SIVand FeLVand/or fusion inhibitors, as a
function of temperature. L, lamellar; H, inverse hexagonal; Q, inverse cubic. Data from samples indicated with an asterisk came from a previous study [17].
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We have previously reported the micellization of the
lamellar phase with as little as 2% CBZ-D-FFG. With the
similar effect of SIVon the lamellar phase, it is not surprising
that their combination dramatically increases the breakdown
of that phase. In contrast, the lamellar stabilization properties
of LPC are maintained in the presence of SIV. This disparity
on the effect on lamellar bilayers between CBZ-D-FFG andLPC is shown dramatically when they are combined. In only
the dilute samples of CBZ-D-FFG and LPC were lamellar
phases identifiable. In all cases of 5%CBZ-D-FFGwith LPC,
a single diffraction peak at large d-spacing (70 A˚) was seen,
precluding the identification of the phase. The addition of
FeLVor SIV restored the lamellar phase.
Considered from another perspective, the mystery phase
seen in the CBZ-D-FFG/LPC combination samples is seen
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lipids. LPC forms type I (headgroup exposed) tightly curved
micelles, thus we might conclude the peptide (SIV and/or
CBZ-D-FFG)-dissolved lipids are type II, where the lipid
acyl-chain that might be exposed to the water is protected by
the peptides. In combination, LPC is structure-stabilizing by
offsetting the preference for SIV and CBZ-D-FFG for the
hydrocarbon core of a curved monolayer. The large d-
spacing of the mystery phase may then be explained as a
swollen lamellar phase, where the peptides have been
sequestered into the centre of the bilayer, increasing its
fluctuations, and in turn its overall d-spacing.
3.2.2. Hexagonal and cubic phases
Both fusion inhibitors have nearly the same effect on the
formation of the hexagonal and cubic phases in the presence
of SIV. For 1% SIV, TH and TQ are slightly raised by the
inhibitor. For 2% SIV the HII phase is restored, and TH is
slightly lower than in 1% SIV. The Q phase is no longer
transient, and TQ is even slightly higher than in 1% SIV.
When combined, CBZ-D-FFG and LPC drive the lipids to a
Q phase that is highly metastable at elevated temperatures.
This Q phase overcomes any effects of the SIV and FeLV
peptides, although FeLV is clearly more potent as the onset
of the Q phase is delayed by 10 jC. The similarity of effects
on the non-lamellar phases, despite the profound differences
on the lamellar phase, is significant. The stable non-lamellar
phase outwith the normal fusion pathway is a cubic phase
with d-repeat of 160–220 A˚. Hexagonal phases, and pre-
sumably hexagonal and fusion precursors, are eliminated
entirely.
3.3. The HII phase and fusion pathways
DOPE-Me was chosen for these experiments because of
its ability to monitor the effects of fusion agents on
monolayer curvature strain. Our previous work with FeLV
peptide and fusion inhibitors [17] has told us that there is
some feature of the action of fusion peptides that is revealed
by their ability to induce inverse hexagonal phases, which is
quite separate from their similar ability to induce cubic
phases. The lamellar–hexagonal pathway (in DOPE-Me)
must share common ground with fusion pathway (in other
lipids) and this feature must not be present in all lamellar–
cubic pathways (there are many cubic phases and there
many be many transition pathways). Although membrane
curvature-strain clearly plays an important role in fusion, it
appears that it is not the only factor involved.
A fluid monolayer is able to respond to a non-zero value
of spontaneous curvature by deforming into a curved
surface. In this way, the monolayer can accommodate
substantial discrepancies between the cross-sectional area
per lipid at the headgroup region (Ah) and the corresponding
area of the fatty acyl chains (Ac). However, in a bilayer this
flexibility is frustrated by the opposing tendencies of the
two monolayers, as well as the entropic energy cost of waterexposure in the hydrocarbon region. In a planar bilayer, the
area per phospholipid molecule is assumed to be constant at
all depths of the bilayer (Ah =Ac). Increasing temperature
will tend to expand the tail region (Ac) more than the
headgroups (Ah), due to the increased conformational dis-
order of the chains, thereby increasing the frustration [25].
This build up of frustration is energetically unfavourable
and eventually the system must reduce it by rearrangement
of the phospholipids into a curved phase, such as the
inverted hexagonal (HII) or inverse cubic (QII) phases.
One way of understanding the effect of fusion peptides
and inhibitors upon phospholipid phase transitions is to
consider their role in increasing or reducing the frustration
within bilayers, as the temperature is steadily increased.
The monolayer curvature strain hypothesis predicts that
the addition of agents that affect the curvature strain (such as
fusion peptides or inhibitors) should change the Gaussian
curvature, at any given temperature, in those phases where
such a change is possible. Agents that increase Ac relative to
Ah should result in structures with a reduced radius of
curvature, and those that increase Ah relative to Ac should
show an increase in radius of curvature. One of the most
remarkable findings of the present study is how small is the
effect of fusion peptides or fusion inhibitors on the lattice
repeat of the HII phase in DOPE-Me. In our measurements,
the change is only just above the level of experimental error.
Colotto et al. [18] have reported that SIV peptide reduces dQ
by a very small amount ( < 0.25 A˚); a mutant, non-fuso-
genic, analogue of the peptide had no measurable effect at
all. Fig. 1 shows that, when plotted on the same vertical
scale as the lamellar and cubic data, the repeat distance at
any given temperature and, therefore, the radius of curvature
of the HII phase remain effectively unchanged, no matter
which agents are present. It is only when the vertical scale is
exaggerated, as in the inset panel, that small differences in
dQ appear, at a level that is close to the limits of experi-
mental error. The presence or absence of peptides or
inhibitors changes the temperature at which the onset of
HII phase occurs, but does not change the lattice dimensions.
It could be that these agents only affect small, localised
regions, and their concentration is too low to have a visible
effect on dQ. If this were true, it would be reasonable to
expect to see an increase in the mosaic spread of the HII
samples, reflected in the width of the diffraction peaks.
However, the FWHM of the first-order Bragg peaks from all
HII samples (with/without peptide/inhibitors) is 0.03F 0.02
A˚ 1 ( q). The peaks do not get broader with peptide or
inhibitors, implying that these agents do not disrupt the
inverse hexagonal structure, even in localised areas. This
may explain why higher concentrations of peptide seem to
be less effective in promoting HII phase. It is almost as if the
peptides are most effective when they induce earlier phase
transitions, without modifying the actual structure formed.
In summary, we have reconfirmed our earlier hypothesis
that precursors of membrane fusion are common to the
lamellar to inverted hexagonal phase. The mechanism of
T.A. Harroun et al. / Biochimica et Biophysica Acta 1617 (2003) 62–6868bilayer destabilization between the fusion peptides SIV and
FeLV differs due to their folded conformational lengths;
SIV acts on leaflets of lipids interacting within the hydro-
carbon matrix, while FeLV prefers mixing into curved
bilayers (such as the HII phase). The net destabilization
effect leads to fusion. When CBZ-D-FFG or LPC is added,
they tend to undo curvature-strain effects and promote Q
phases at higher temperatures, bypassing the intermediate
structures that lead to hexagonal formation. These insights
should lead us to refine theories of the mechanism of
membrane fusion, such as tests for whether lipid mixing
between leaflets occurs during the fusion process.Acknowledgements
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